Topic
Solid lipid nanoparticle
About: Solid lipid nanoparticle is a research topic. Over the lifetime, 3175 publications have been published within this topic receiving 127912 citations. The topic is also known as: LNP & SLN.
Papers published on a yearly basis
Papers
More filters
TL;DR: The pharmacokinetic study of optimised SLNs conducted in male Albino Wistar rats showed 2.08-fold increase in relative bioavailability than that of NMD solution, when administered orally and these NMD-SLNs are considered to be promising vehicles for oral delivery.
105 citations
Patent•
02 Apr 1997
TL;DR: In this paper, lipophilic substances of poor oral bioavailability are mixed with at least one solid fat and phospholipid to obtain a dried solid composition suitable as an oral dosage form.
Abstract: Lipophilic substances of poor oral bioavailability are mixed with at least one solid fat and phospholipid to obtain a dried solid composition suitable as an oral dosage form The solid lipid compositions are exemplified for food additives or dietary supplements such as Coenzyme Q10 and for pharmaceuticals such as dexanabinol The Coenzyme Q10-dry lipid mixtures shows improved drug release in vitro and enhanced oral bioavailability in vivo compared to a commercial CoQ10 formulation The dexanabinol-dry lipid mixture similarly shows greatly enhanced oral bioavailability compared to known formulations
105 citations
01 Nov 2016
TL;DR: The developed nanoformulation appears to be proficient in targeted delivery of GmcH with improved therapeutic effectiveness and enhanced safety.
Abstract: Gemcitabine (GmcH) is an effective anti-cancer agent used in the chemotherapy of lung cancer. However, the clinical applications of GmcH has been impeded primarily due to its low blood residence time, unfavorable pharmacokinetic and pharmacodynamic (PK/PD) profile, and poor penetration in the complex environment of lung cancer cells. Thus, the present study aims to formulate GmcH loaded mannosylated solid lipid nanoparticles (GmcH-SLNs) for improving its drug uptake into the lung cancer cells. GmcH-SLNs were prepared by emulsification and solvent evaporation process, and surface modification was done with mannose using ring opening technique. The cellular toxicity and cell uptake studies were performed in A549 lung adenocarcinoma cell line. The developed nanoformulation appears to be proficient in targeted delivery of GmcH with improved therapeutic effectiveness and enhanced safety.
105 citations
TL;DR: HSA-grafted SLNs and NLCs can be effective formulations in the delivery of NVP for viral therapy in mice fabricated for formulating nevirapine.
104 citations
TL;DR: It is suggested that SLNs can be successfully converted to physically superior NLCs, which have the potential to be developed further as ocular drug delivery systems for ACV.
Abstract: The objective of the present investigation was to improve the ocular bioavailability of acyclovir by incorporating it into solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs). This required optimization of the process parameters, such as type of lipid, drug to lipid ratios, type and concentration of surfactants, and type and amount of liquid lipids used in the formulations. SLNs and NLCs were prepared by the modified hot oil in water microemuslion method. The prepared nanoparticles were evaluated for their particle size, zeta potential, entrapment efficiency, solid state characteristics, surface morphology, in vitro drug release, and permeation through excised cornea. The prepared nanoparticles were spherical and within the size range suitable for ocular drug delivery (400–777.56 nm). Incorporation of liquid oil in the structure of SLNs resulted in the formation of NLCs with high entrapment efficiency (25–91.64%) compared to SLNs (11.14%). The drug release from SLNs and NLCs was rath...
104 citations